Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Melanotan-I

Afamelanotide, MT-I, [Nle4-D-Phe7]-α-MSH, Scenesse, CUV-1647

Quick Stats
Studies 225
Trials 100
Score 3
2017 pubmed 21 citations

Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review.

Habbema. Louis L; Halk. Anne Berthe AB; Neumann. Martino M; Bergman. Wilma W

Key Findings

  • Unregulated melanotan I and II are often of unknown purity, dosage, and formulation, increasing safety risks.
  • Case reports link these peptides to melanocytic changes in existing moles and the appearance of new dysplastic nevi, with a few instances of melanoma development.
  • Regulatory agencies and dermatology societies have issued warnings about the unregulated use of melanotan peptides.

Practical Outcomes

  • If you’re considering melanotan for tanning or any other benefit, avoid unregulated sources and stick to medically approved products like afamelanotide only under professional supervision. Monitor any existing moles closely and seek dermatological evaluation if you notice changes after any use. Treat melanotan use as a high‑risk experiment rather than a safe, evidence‑based protocol.

Summary

The review warns that buying and using unregulated melanotan I or II (synthetic alpha‑MSH peptides) can be dangerous. Because the products aren’t tested, you don’t know the exact dose or how they’re made, and they have been linked to skin problems, including changes in moles and a few reported melanomas. The only approved alpha‑MSH drug, afamelanotide, has been studied and is considered safe for specific medical uses.

Abstract

Recently, the unregulated use of untested synthetic alpha-melanocyte-stimulating hormone (α-MSH) analogues, commonly known as melanotan I and II, appears to have increased. These analogues are primarily used for their tan-stimulating effects. Dermatologists see many patients in their clinic who tan. This review provides an overview of the risks of the unregulated use of these substances. Other topics discussed here include the history and safety of afamelanotide, which is the only α-MSH analogue that is approved for use in a limited number of medical indications. Although afamelanotide has been thoroughly tested and deemed safe, illegal melanotans are likely risky for several reasons. There are questions regarding the preparation, administration, and dosage of these substances. In addition to these general risks, increasing numbers of case reports indicate that the unregulated use of both melanotan I and II is associated with cutaneous complications, particularly melanocytic changes in existing moles and newly emerging (dysplastic) nevi. Four case reports have described melanomas emerging from existing moles either during or shortly after the use of melanotan. Although conclusive evidence linking these phenomena is lacking, publications have stressed the importance of awareness that melanotan is a part of a 'tanning culture' in certain subpopulations. Multiple national health organizations have issued safety warnings regarding the use of melanotan I and II.

Study Information

Provider

pubmed

Year

2017

Date

2017-03-07T00:00:00.000Z

DOI

10.1111/ijd.13585

Citations

21

References

44